Medpace Holdings Inc vs Visa Inc — how do they compare? Medpace Holdings Inc trades at $530.58 (market cap $15.08B), while Visa Inc trades at $357.76 (market cap $685.71B). The key difference: Visa Inc is far larger — about 45.5× Medpace Holdings Inc's market cap, and Visa Inc pays a 0.74% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | V | |
|---|---|---|
Market Cap | $15.08B | $685.71B |
Sector | Technology | Financials |
52-Week High | $620.59 | $365.14 |
52-Week Low | $308.88 | $295.52 |
Enterprise Value | $14.55B | $696.30B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Visa (V) trades at $358.50, showing minimal daily movement (-0.02%) with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.31 versus $3.10 expected, and maintains exceptional profitability with 51.68% net income margin. Recent developments include the launch of Intelligent Commerce Connect to facilitate AI-powered commerce and expanded stablecoin partnerships.
Visa presents a compelling long-term investment case with 85% analyst buy ratings and $396.70 consensus price target suggesting 11% upside. The company's dominant payment network position, AI integration initiatives, and strong cash flow generation support continued growth, though investors should monitor competitive threats from fintech disruption and regulatory pressures that could impact future performance.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →